Clinical Trials Directory

Trials / Conditions / KRAS G12C Mutation

KRAS G12C Mutation

7 registered clinical trials studyying KRAS G12C Mutation — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingFulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSC
NCT07492342
Jianxing HePhase 2
Enrolling By InvitationIntegrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT07122882
Chang Gung Memorial Hospital—
Not Yet Recruiting5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Pat
NCT07124884
Federation Francophone de Cancerologie DigestivePhase 2
Not Yet RecruitingThe Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Sec
NCT06959589
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2
RecruitingA Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants Wit
NCT06720987
Kumquat Biosciences Inc.Phase 1
UnknownStudy of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
NCT06117371
BeBetter Med IncPhase 1
Active Not RecruitingGenetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796
Alliance for Clinical Trials in OncologyPhase 2